Reviewer’s report

Title: CCNE1 Amplification Is Associated with Poor Prognosis in Patients with Triple Negative Breast Cancer

Version: 0 Date: 01 Dec 2018

Reviewer: Gopal Chakraborti

Reviewer’s report:

The article "CCNE1 Amplification Is Associated with Poor Prognosis in Patients with Triple Negative Breast Cancer" was well scientific written research paper by the authors. The work has good impact on TNBC patients for targeted therapy suppressing CCNE1 for the betterment of the prognosis of TNBC patients. However, a few comments and additional work are suggested to validate the hypothesis/ findings

Comments

1. The supplement figure showed the high expression of CCNE1 and TPX2 in compared to normal and TNBC patients. However, authors showed only CCNE1 expressions (mRNA profiling) in the figure 4. Why it is so. Is there any correlation of CCNE1 and TPX2 in TNBC patients in mRNA level? Please address this question.

2. Why TPX2 is not included in the title of the article?

3. The protein profiling like ELISA or Western blot should be done for the genes mentioned in figure 1 e.g. p53, Pi3K, mTOR, etc.

Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.

Yes

Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.

Yes

Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.

Yes
Are you able to assess any statistics in the manuscript or would you recommend an additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further assessment in your comments to the editors.

I am able to assess the statistics

Quality of written English
Please indicate the quality of language in the manuscript:

Acceptable

Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:

1. Have you in the past five years received reimbursements, fees, funding, or salary from an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

2. Do you hold any stocks or shares in an organisation that may in any way gain or lose financially from the publication of this manuscript, either now or in the future?

3. Do you hold or are you currently applying for any patents relating to the content of the manuscript?

4. Have you received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript?

5. Do you have any other financial competing interests?

6. Do you have any non-financial competing interests in relation to this paper?

If you can answer no to all of the above, write 'I declare that I have no competing interests' below. If your reply is yes to any, please give details below.

I declare that I have no competing interests.

I agree to the open peer review policy of the journal. I understand that my name will be included on my report to the authors and, if the manuscript is accepted for publication, my named report including any attachments I upload will be posted on the website along with the authors' responses. I agree for my report to be made available under an Open Access Creative Commons CC-BY license (http://creativecommons.org/licenses/by/4.0/). I understand that any comments which I do not wish to be included in my named report can be included as confidential comments to the editors, which will not be published.

I agree to the open peer review policy of the journal